Veracyte, Inc. completed its acquisition of Convergent Genomics on September 14, 2026, pursuant to a merger agreement dated September 10, 2026. Veracyte paid $150 million in aggregate cash consideration to Convergent securityholders, with potential additional payments of up to $30 million based on specified milestones related to UroAmp publications and reimbursement efforts. The acquisition adds Convergent’s UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio, targeting non-muscle invasive bladder cancer care. Veracyte expects to commercialize the initial test in late 2028. Veracyte is a global diagnostics company that uses molecular tests to assess tumor biology and guide cancer care decisions.

Veracyte, Inc. reported financial results for the quarter ended June 30, 2026, announcing total revenue of $150.3 million, a 15% year-over-year increase driven by Decipher and Afirma testing growth. The company recorded GAAP net income of $25.5 million ($0.31 diluted EPS) and adjusted EBITDA of $44.0 million (29.2% margin). Veracyte raised its full-year 2026 revenue guidance to $590–$596 million, reflecting a 14–15% growth rate, while maintaining an adjusted EBITDA margin expectation above 26%. The company also launched the Prosigna LDT and TrueMRD for MIBC tests. Veracyte operates in the cancer diagnostics industry, providing molecular genomic tests to assess tumor biology.

On June 10, 2026, stockholders approved an amendment to the Company's 2023 Equity Incentive Plan, increasing the number of reserved shares of Common Stock for issuance by 3,500,000. Other annual meeting results included the election of nine directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026, and the non-binding advisory approval of named executive officer compensation. Veracyte operates in the healthcare industry, developing genomic diagnostics to inform patient management.